Watson Pharmaceuticals, Inc. (NYSE: WPI) has been granted final approval by the USFDA for its Abbreviated New Drug Application (ANDA) for levonorgestrel / ethinyl estradiol tablets USP, 0.15 mg / 0.03 mg.
A Levonorgestrel / ethinyl estradiol tablet, USP is the generic version of Duramed Pharmaceuticals' Seasonale® extended-cycle oral contraceptive, which is indicated for prevention of pregnancy.
Watson Pharmaceuticals, Inc. intends to launch the product immediately under the trade name QUASENSE™.
Source: Watson Pharmaceuticals, Inc.
Comment Preview